相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension
Steven R. Cummings et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
Remodeling- and Modeling-Based Bone Formation With Teriparatide Versus Denosumab: A Longitudinal Analysis From Baseline to 3 Months in the AVA Study
David W. Dempster et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial
J. P. Bilezikian et al.
OSTEOPOROSIS INTERNATIONAL (2018)
Effectiveness of a two-step population-based osteoporosis screening program using FRAX: the randomized Risk-stratified Osteoporosis Strategy Evaluation (ROSE) study
K. H. Rubin et al.
OSTEOPOROSIS INTERNATIONAL (2018)
Abstracts of the ECTS Congress 2018
CALCIFIED TISSUE INTERNATIONAL (2018)
Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study
Michael R. McClung et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab
Felicia Cosman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial
Piet Geusens et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis
Henry G. Bone et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial
Lee Shepstone et al.
LANCET (2018)
Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial
David L. Kendler et al.
LANCET (2018)
Abaloparatide Is an Anabolic, but Does It Spare Resorption?
T. John Martin et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2017)
Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases
Athanasios D. Anastasilakis et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2017)
Response to Letter: Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation
Olivier Lamy et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial
Bente L. Langdahl et al.
LANCET (2017)
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
Kenneth G. Saag et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Osteoporosis treatment: recent developments and ongoing challenges
Sundeep Khosla et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension
Henry G. Bone et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial
Andrew Grey et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2017)
Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: The ACTIVE phase 3 trial
Carolina A. Moreira et al.
BONE (2017)
Bone remodeling markers: so easy to measure, so difficult to interpret
E. Seeman et al.
OSTEOPOROSIS INTERNATIONAL (2016)
Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports
B. Aubry-Rozier et al.
OSTEOPOROSIS INTERNATIONAL (2016)
Multiple clinical vertebral fractures following denosumab discontinuation
A. D. Anastasilakis et al.
OSTEOPOROSIS INTERNATIONAL (2016)
Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics
A. W. Popp et al.
OSTEOPOROSIS INTERNATIONAL (2016)
Recurrence of bilateral atypical femoral fractures associated with the sequential use of teriparatide and denosumab: a case report
S. K. Ramchand et al.
OSTEOPOROSIS INTERNATIONAL (2016)
Six Weeks of Daily Abaloparatide Treatment Increased Vertebral and Femoral Bone Mineral Density, Microarchitecture and Strength in Ovariectomized Osteopenic Rats
Hila Bahar et al.
CALCIFIED TISSUE INTERNATIONAL (2016)
Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis A Randomized Clinical Trial
Paul D. Miller et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
A Crisis in the Treatment of Osteoporosis
Sundeep Khosla et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2016)
Effects of Two Years of Teriparatide, Denosumab, or Both on Bone Microarchitecture and Strength (DATA-HRpQCT study)
J. N. Tsai et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
P. D. Miller et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
F. Cosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Clinical vertebral fractures following denosumab discontinuation
Stergios A. Polyzos et al.
ENDOCRINE (2016)
Co-administration of Antiresorptive and Anabolic Agents: A Missed Opportunity
Ego Seeman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2015)
The Effect of 6 Versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT)
Dennis M. Black et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2015)
Sustained Modeling-Based Bone Formation During Adulthood in Cynomolgus Monkeys May Contribute to Continuous BMD Gains With Denosumab
Michael S. Ominsky et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2015)
Effects of Abaloparatide, a Human Parathyroid Hormone-Related Peptide Analog, on Bone Mineral Density in Postmenopausal Women with Osteoporosis
Benjamin Z. Leder et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial
Benjamin Z. Leder et al.
LANCET (2015)
Short-term and long-term effects of osteoporosis therapies
Ian R. Reid
NATURE REVIEWS ENDOCRINOLOGY (2015)
Cortical Bone: A Challenging Geography
Roger Zebaze et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2015)
Differing effects of denosumab and alendronate on cortical and trabecular bone
Roger M. Zebaze et al.
BONE (2014)
Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: Efficacy and safety results from a randomized open-label study
C. Roux et al.
BONE (2014)
Bone cell-independent benefits of raloxifene on the skeleton: A novel mechanism for improving bone material properties
Maxime A. Gallant et al.
BONE (2014)
Duration of Antiresorptive Effects of Low-Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized, Placebo-Controlled Trial
Andrew Grey et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2014)
Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research
Elizabeth Shane et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2014)
Cortical Porosity Identifies Women With Osteopenia at Increased Risk for Forearm Fractures
Yohann Bala et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2014)
Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate
J. P. Brown et al.
OSTEOPOROSIS INTERNATIONAL (2014)
A new method of segmentation of compact-appearing, transitional and trabecular compartments and quantification of cortical porosity from high resolution peripheral quantitative computed tomographic images
R. Zebaze et al.
BONE (2013)
Reduction in the Risk of Clinical Fractures After a Single Dose of Zoledronic Acid 5 Milligrams
I. R. Reid et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial
Joy N. Tsai et al.
LANCET (2013)
An evaluation of the Fracture Risk Assessment Tool (FRAX®) as an indicator of treatment efficacy: the effects of bazedoxifene and raloxifene on vertebral, nonvertebral, and all clinical fractures as a function of baseline fracture risk assessed by FRAX®
J. -M. Kaufman et al.
OSTEOPOROSIS INTERNATIONAL (2013)
The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)
Dennis M. Black et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody
Paul J. Kostenuik et al.
BONE (2011)
Greater magnitude of turnover suppression occurs earlier after treatment initiation with risedronate than alendronate
Matthew R. Allen et al.
BONE (2011)
Effects of Intravenous Zoledronic Acid Plus Subcutaneous Teriparatide [rhPTH(1-34)] in Postmenopausal Osteoporosis
Felicia Cosman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Effect of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover: Six-Year Results of a Phase 2 Clinical Trial
Paul D. Miller et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass
Henry G. Bone et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis
H. M. Macdonald et al.
OSTEOPOROSIS INTERNATIONAL (2011)
Potential Mediators of the Mortality Reduction With Zoledronic Acid After Hip Fracture
Cathleen S. Colon-Emeric et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Microarchitectural Deterioration of Cortical and Trabecular Bone: Differing Effects of Denosumab and Alendronate
Ego Seeman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Effects of Denosumab on Bone Histomorphometry: The FREEDOM and STAND Studies
Ian R. Reid et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study
Roger M. D. Zebaze et al.
LANCET (2010)
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Steven R. Cummings et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial
Paul D. Miller et al.
BONE (2008)
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy
R. G. G. Russell et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Finite element analysis based on in vivo HR-pQCT images of the distal radius is associated with wrist fracture in postmenopausal women
Stephanie Boutroy et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
Zoledronic acid and clinical fractures and mortality after hip fracture
Kenneth W. Lyles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Raloxifene enhances material- level mechanical properties of femoral cortical and trabecular bone
Matthew R. Allen et al.
ENDOCRINOLOGY (2007)
Increases in BMD correlate with improvements in bone microarchitecture with Teriparatide treatment in postmenopausal women with osteoporosis
Peiqi Chen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
Dennis M. Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: The risedronate and alendronate (REAL) cohort study
S. L. Silverman et al.
OSTEOPOROSIS INTERNATIONAL (2007)
Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice
Rana Samadfam et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
An estimate of the worldwide prevalence and disability associated with osteoporotic fractures
O. Johnell et al.
OSTEOPOROSIS INTERNATIONAL (2006)
Raloxifene enhances vertebral mechanical properties independent of bone density
Matthew R. Allen et al.
BONE (2006)
Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men
Joel S. Finkelstein et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
The molecular mechanism of nitrogen-containing bisphosphonates as anti osteoporosis drugs
Kathryn L. Kavanagh et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Half the burden of fragility fractures in the community occur in women without osteoporosis. When is fracture prevention cost-effective?
Kerrie M. Sanders et al.
BONE (2006)
A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: Early actions of teriparatide
R Lindsay et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
The population burden of fractures originates in women with osteopenia, not osteoporosis
J. A. Pasco et al.
OSTEOPOROSIS INTERNATIONAL (2006)
Bone mineral density thresholds for pharmacological intervention to prevent fractures
ES Siris et al.
ARCHIVES OF INTERNAL MEDICINE (2004)
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis
DM Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
The effects of parathyroid hormone, alendronate, or both in men with osteoporosis
JS Finkelstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys
SY Smith et al.
BONE (2003)
Misconceptions (2): Turnover is always higher in cancellous than in cortical bone
AM Parfitt
BONE (2002)
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
RM Neer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
分享论文
